GSK5764227 + durvalumab

GSK5764227 + durvalumab is a **combination therapy** under investigation for advanced solid tumors and extensive-stage small-cell lung cancer. **GSK5764227** (also called GSK’227, HS-20093) is a **B7-H3-targeted antibody-drug conjugate (ADC)** consisting of a human anti–B7-H3 monoclonal antibody linked to a topoisomerase I inhibitor via a protease-cleavable linker[4]. It targets the B7-H3 (CD276) immune checkpoint, which is often overexpressed in multiple solid tumors and is associated with immune evasion[4][7]. **Durvalumab** is a monoclonal antibody that inhibits PD-L1, thus blocking its interaction with PD-1 and enabling T-cell–mediated antitumor immunity. The combination is being evaluated to determine whether dual targeting of B7-H3 and PD-L1 improves efficacy beyond either agent alone, particularly in difficult-to-treat cancers like relapsed or refractory osteosarcoma and extensive-stage small-cell lung cancer[1][3][7][9]. GSK is the primary developer and sponsor for this combination. Key indications under study include advanced solid tumors, relapsed or refractory osteosarcoma, and extensive-stage small-cell lung cancer[1][3][4][5].